PDCD1LG2 and cancer: The development of checkpoint inhibitors targeting PD-1 has led to the widespread clinical use of monoclonal antibodies (MAbs) such as pembrolizumab, which effectively block PD-1 interactions with PD-L1 and PD-L2, restoring T-cell activation in cancer immunotherapy.